Tevogen Bio Holdings Inc

TVGN USD0.0001
Create an alert
Sell$5.90
Buy$6.90
$0.38 (5.97%)
Last updated today at
Back to dashboard

Company Information

About this company

Tevogen Inc., formerly Tevogen Bio Holdings Inc., is a socially integrated healthcare enterprise. The Company leverages artificial intelligence and precision T cell therapy platforms, and engagements with global technology companies to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, its lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. It is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and insurance solutions for healthcare providers.

Key people

Ryan Saadi
Chairman of the Board, Chief Executive Officer
Kirti Desai
Chief Financial Officer
Neal Flomenberg
Chief Scientific Officer and Global R&D Lead
Sadiq Khan
Chief Commercial Officer
Jeffrey Feike
Independent Director
Keow Lin Goh
Independent Director
Curtis Patton
Independent Director
Susan M. Podlogar
Independent Director
Victor Sordillo
Independent Director
Click to see more

Key facts

  • Shares in issue
    6.51m
  • EPIC
    TVGN
  • ISIN
    US88165K2006
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $43.95m
  • Employees
    18
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.